Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aduro Material AB currently manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action under review. This active matter is being handled by 1 distinct examiner, indicating a concentrated prosecution effort for the current portfolio. The alignment of the workload under 1 distinct examiner suggests a specific point of contact for the company's intellectual property filings.
The prosecution activity is localized within 1 distinct art unit. RAO, SAVITHA M is identified as the busiest examiner for the company, currently overseeing 1 busiest examiner pending action. This examiner accounts for the entirety of the company's pending workload, as the busiest examiner pending count of 1 matches the total of 1 pending office action for the portfolio. This concentration in 1 distinct art unit implies a narrow technical focus for the active applications.
Practitioners should note the degree of examiner concentration in this portfolio. With 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy is currently dependent on a single point of review within the Biotechnology & Pharmaceuticals sector. This structure means that the outcome of the current pending matter will be determined by the specific examination practices of RAO, SAVITHA M.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291635 | CONTROLLED DRUG RELEASE MATERIAL | RAO, SAVITHA M | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291635 | CONTROLLED DRUG RELEASE MATERIAL | RAO, SAVITHA M | 1691 | §103 | Non-Final OA | — | Pending | Jan 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAduro Material AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Savitha M Rao has the most, with 1 of Aduro Material AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
